[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Citryll BV\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":112},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,61,88],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100592423","phase-2-a-study-with-cit-013-in-hs-patients-100592423",false,"NCT06993233","A Study With CIT-013 in HS Patients","A Phase 2a Double Blind, Randomized, Parallel Arm, Placebo-controlled Trial to Investigate the Effects of Two Dose Levels of CIT-013 on Disease Activity in Patients With Hidradenitis Suppurativa","Citylights","Inclusion Criteria:\n\n* Male or female participants with HS of more than 6 months duration,\n* 18 years of age at screening visit,\n* Hidradenitis suppurativa lesions present in ≥ 2 distinct anatomic areas, one of which is Hurley Stage II or III (according to Hurley classification system),\n* A total abscess and inflammatory nodule (AN) count of ≥ 5 at screening and Day 1 prior to enrollment\u002Frandomization,\n* Participant must have had an inadequate response to oral antibiotics OR exhibited recurrence after discontinuation to, OR demonstrated intolerance to, OR have a contraindication to oral antibiotics for treatment of their HS,\n* Total draining tunnel count less than 20\n\nExclusion Criteria:\n\n\\- Participants for whom an approved therapy with demonstrated clinical benefit is indicated, available and expected to be tolerated, OR choose to proceed with standard of care treatment options over the IP (after being appropriately informed of the treatment options, risks, and benefits).\n\nAny current and\u002For recurrent clinically significant skin condition in the treatment area other than HS,\n\n* Prior treatment with a recombinant therapeutic protein during the 6 weeks before baseline\n* Prior treatment with any of the following medications before baseline:\n\n  1. Any other systemic therapy for HS (28 days before baseline)\n  2. Any IV anti-infective therapy (14 days before baseline)\n* History of malignancy with exception of non-melanoma skin cancer that has been excised and cured,","ALL","18 Years",{"count":20,"type":21},96,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The goal of this clinical trial is to learn if CIT-013 works to treat Hidradenitis Suppurativa in adults. It will also learn about the safety of CIT-013. The main questions it aims to answer are:\n\nDoes CIT-013 lower the disease activity of HS patients? What medical problems do participants have when receiving CIT-013? Researchers will compare CIT-013 to a placebo (a look-alike substance that contains no drug) to see if CIT-013 works to treat the symptoms of HS.\n\nParticipants will:\n\nTake receive 50 or 100 mg CIT-013 or placebo every other week for 12 weeks Visit the clinic once every 2 weeks for checkups and tests Keep monitor their symptoms during this period",[27],"Hidradenitis Suppurativa (HS)","RECRUITING","2026-05-20",{"date":31,"type":32},"2026-05-22","ACTUAL",{"date":34,"type":32},"2025-10-31",{"date":36,"type":21},"2027-07",{"name":38,"class":39},"Citryll BV","INDUSTRY",28,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":55,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":59,"locationsCount":60},"100559694","phase-2-a-study-with-cit-013-in-ra-patients-100559694","NCT06567470","A Study With CIT-013 in RA Patients","A Phase IIa Double-Blind, Randomized, Parallel-Arm, Placebo-Controlled Trial To Investigate The Effects Of Three Dose Levels Of CIT-013 On Disease Activity In Patients With Moderately Active Rheumatoid Arthritis.","Citydream","Inclusion Criteria:\n\n* Male or female patients with RA according to the 2010 classification criteria of the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) ≥ 3 months prior to screening\n* Aged 18-85\n* DAS28-CRP ≥ 3.2, with ≥ 3 Swollen Joints, and ≥ 3 Tender Joints, and CRP ≥ ULN at screening and confirmed prior to randomization\n* Stable on a conventional synthetic disease modifying antirheumatic drug for ≥ 4 weeks (csDMARD). This drug must have been used for ≥ 3 months.\n\nExclusion Criteria:\n\n* High clinical activity or disease severity requiring the immediate start of a biological DMARD (bDMARD) or targeted synthetic DMARD (tsDMARD).\n* Contra-indication for CIT-013\n* Current inflammatory joint disease other than RA (Sjogren with active disease is included).\n* The washout period for bDMARD or JAKi prior to the first dose of investigational product should be at least:\n\n  1. ≥ 1 week for etanercept;\n  2. ≥ 4 weeks for adalimumab, infliximab, certolizumab, golimumab, abatacept, tocilizumab, and sarilumab;\n  3. ≥ 6 months year for rituximab;\n  4. ≥ 2 weeks for tsDMARD (either investigational or commercially available treatment).\n* Treated with ≥ 3 bDMARD or tsDMARD\n* Injectable corticosteroids or treatment with \\> 10 mg\u002Fday dose of oral prednisolone or equivalent within 4 weeks prior to screening.",{"count":50,"type":21},88,[24],"The goal of this clinical trial is to learn if CIT-013 works to treat rheumatoid arthritis in adults. It will also learn about the safety of CIT-013. The main questions it aims to answer are:\n\nDoes CIT-013 lower the disease activity of RA patients? What medical problems do participants have when receiving CIT-013? Researchers will compare CIT-013 to a placebo (a look-alike substance that contains no drug) to see if CIT-013 works to treat the symptoms of RA.\n\nParticipants will:\n\nTake receive CIT-013 or placebo every other week for 6 weeks and 50 mg CIT-013 for 6 weeks Visit the clinic once every 2 weeks for checkups and tests Keep monitor their symptoms during this period",[54],"Rheumatoid Arthritis",{"date":31,"type":32},{"date":57,"type":32},"2025-07-29",{"date":36,"type":21},{"name":38,"class":39},24,{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":69,"sex":17,"minAge":18,"maxAge":70,"enrollmentInfo":71,"targetDuration":4,"studyType":22,"phases":73,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},"100631379","phase-1-phase-1-trial-to-evaluate-150-mg-subcutaneous-cit-013-100631379","NCT07499908","Phase 1 Trial to Evaluate 150 mg Subcutaneous CIT-013","A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose Trial to Evaluate 150 mg Subcutaneous CIT-013 Administration in Healthy Adult Volunteers","Citysky","Inclusion Criteria:\n\nHealthy men or women, 18 to 75 years of age (inclusive) at screening.\n\nExclusion Criteria:\n\nEvidence of any active or chronic disease or condition that could interfere with, or for which the treatment might interfere with, the conduct of the trial, or that would pose an unacceptable risk to the participant in the opinion of the Investigator.",true,"75 Years",{"count":72,"type":21},10,[74],"PHASE1","This is a phase 1, double-blind, randomized, placebo-controlled, single center, repeat-dose trial for the assessment of safety, tolerability, bioavailability and pharmacokinetic profiles of 150 mg CIT-013 in healthy adult volunteers",[77],"Healthy Adult","NOT_YET_RECRUITING","2026-04-08",{"date":81,"type":32},"2026-04-13",{"date":83,"type":21},"2026-05-31",{"date":85,"type":21},"2026-10-31",{"name":38,"class":39},1,{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":17,"minAge":96,"maxAge":97,"enrollmentInfo":98,"targetDuration":4,"studyType":22,"phases":100,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":87},"100604318","phase-2-pet-based-imaging-of-radiolabeled-cit-013-100604318","NCT07147959","PET-Based Imaging of Radiolabeled CIT-013","PET-Based Imaging to Evaluate the Distribution of Radiolabeled CIT-013 in Patients With Inflammatory Mediated Immune Disease","Cityview","Inclusion Criteria:\n\n* Female (of non-childbearing potential) or male between 60-85 years of age (both inclusive).\n* For male participants with female partners of child-bearing potential, an adequate form of contraception must be adhered to, and men must refrain from donating sperm, prior to entry into the trial and for a further 6 months after IP administration.\n* Willing and able to provide written, informed consent.\n\nExclusion Criteria:\n\n* Diagnosed with RA according to the 2010 classification criteria of the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) ≥ 6 months prior to screening (diagnosis based on medical records).\n\nParticipants in Cohort A (active RA) must furthermore meet the following criteria:\n\n\\- Disease Activity Score 28 (DAS28) C-Reactive Protein (CRP) (DAS28-CRP) ≥ 4.2 AND ≥ 1 Swollen Joint AND ≥ 1 Tender Joint prior to screening.","60 Years","85 Years",{"count":99,"type":21},12,[24],"Inflammatory mediated immune diseases (IMIDs), such as rheumatoid arthritis (RA) and hidradenitis suppurativa (HS), are characterized by chronic inflammation resulting from an aberrant immune response. Recent studies have identified neutrophil extracellular traps (NETs) as key contributors to the pathology of these diseases. CIT-013 is a novel humanized monoclonal antibody designed to inhibit NET release and enhance phagocytosis, offering a new potential therapeutic strategy for RA and HS. Previous clinical trials have demonstrated that CIT-013 is well tolerated in both healthy volunteers and patients with RA, with evidence of reduced NET formation and positive effects in active RA cases. Since NET-related inflammation primarily occurs in local tissues, understanding CIT-013's distribution beyond blood measurements is crucial for evaluating its therapeutic potential. This trial therefore uses radiolabeled CIT-013 and Positron Emission Tomography-Computed Tomography (PET-CT) imaging, along with lymph node biopsies, to evaluate the distribution of CIT-013 and target engagement in patients with IMIDs.",[103],"RA","2026-01-28",{"date":106,"type":32},"2026-01-30",{"date":108,"type":32},"2026-01-15",{"date":110,"type":21},"2026-12-01",{"name":38,"class":39},""]